Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors
Authors:
- Teresa GaglianoTeresa Gagliano
- Erica GentilinEGErica Gentilin
- Federico TagliatiFTFederico Tagliati
- Maria Rosaria AmbrosioMAMaria Rosaria Ambrosio
- Giancarlo PansiniGPGiancarlo Pansini
- Ettore C degli UbertiEUEttore C degli Uberti
- Maria Chiara ZatelliMZMaria Chiara Zatelli
Open Access
- 20 May 2011
- journal article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 18 (4) , 439-450
Abstract
Dysregulation of the protein kinase C (PKC) signaling pathway has been implicated in tumor progression. In this study, we investigate the effects of a PKC inhibitor, Enzastaurin, in human pancreatic neuroendocrine neoplasms (PNN) primary cultures and in the human pancreatic endocrine cancer cell line, BON1. To this aim six human PNN dispersed in primary cultures and BON1 cells were treated without or with 1–10 μM Enzastaurin and/or 100 nM IGF1 in the presence or absence of serum. Cell viability and apoptosis were evaluated after 48–72 h; Chromogranin A (CgA) and/or insulin secretion was assessed after 6 h of incubation. PKC expression was investigated by immunofluorescence and western blot. We found that Enzastaurin significantly reduced human PNN primary culture cell viability, as well as CgA and insulin secretion. Moreover, in the BON1 cell line Enzastaurin inhibited cell proliferation at 5 and 10 μM by inducing caspase-mediated apoptosis, and reduced phosphorylation of glycogen synthetase kinase 3β (GSK3β) and of Akt, both downstream targets of PKC pathway and pharmacodynamic markers for Enzastaurin. In addition, Enzastaurin blocked the stimulatory effect of IGF1 on cell proliferation, and reduced CgA expression and secretion in BON1 cells. Two different PKC isoforms are expressed at different levels and have partially different subcellular localization in BON1 cells. In conclusion, Enzastaurin reduces cell proliferation by inducing apoptosis, with a mechanism likely involving GSK3β signaling, and inhibits secretory activity in PNNin vitromodels, suggesting that Enzastaurin might represent a possible medical treatment of human PNN.Keywords
This publication has 38 references indexed in Scilit:
- Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling ContextMolecular Cancer Therapeutics, 2010
- Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative studyInvestigational New Drugs, 2009
- Neuroendocrine Tumors of the PancreasThe Oncologist, 2009
- An Aggressive Surgical Approach Leads to Long-term Survival in Patients With Pancreatic Endocrine TumorsAnnals of Surgery, 2006
- The Selective Protein Kinase C β Inhibitor Enzastaurin Induces Apoptosis in Cutaneous T-Cell Lymphoma Cell Lines through the AKT PathwayJournal of Investigative Dermatology, 2006
- Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell linesMolecular Cancer Therapeutics, 2006
- Insulin-Like Growth Factor-1 Increases Intracellular Calcium Concentration in Human Primary Neuroendocrine Pancreatic Tumor Cells and a Pancreatic Neuroendocrine Tumor Cell Line (BON-1) via R-Type Ca2+ Channels and Regulates Chromogranin A Secretion in BON-1 CellsNeuroendocrinology, 2005
- Rapid Association of Protein Kinase C-ϵ with Insulin Granules Is Essential for Insulin ExocytosisJournal of Biological Chemistry, 2003
- Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase BNature, 1995
- Characterization of a Human Pancreatic Carcinoid in VitroPancreas, 1994